Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Barr Laboratory BRL -- Ignore unavailable to you. Want to Upgrade?

To: E. Graphs who wrote (183)	1/13/2000 5:51:00 PM
From: harkenman	Respond to of 207

Stock closed up today 4 1/4. Seems that the pharma sector is getting the attention it deserves. The following was quoted on BRL: Politically astute management at Barr Labs (NYSE: BRL - news), led by Chairman & CEO, Bruce L. Downey, maintains a buy sider, ``In the case of Barr Labs, you have management that in 1992 took a company that was basically on its death bed and completely turned it around.' biz.yahoo.com Also BRL was recommended as a pick by cbs.marketwatch.com.

To: E. Graphs who wrote (183)	2/25/2000 8:59:00 AM
From: harkenman	Read Replies (1) \| Respond to of 207

Fedl Appeals Court To Hear Prozac Patent Challenge March 8 POMONA, N.Y. -- The federal appeals court in Washington D.C. will hear oral arguments on March 8 concerning Barr Laboratories Inc.'s (BRL) challenge of the patents protecting Eli Lilly & Co. 's (LLY) Prozac anti-depressant treatment. In a press release Wednesday, Barr said the two patents protecting Prozac from competition are invalid. Barr's argument before the appeals court will involve "double patenting" and "best mode" claims. The drug developer said the U.S. District Court in Indiana dismissed these claims at pre-trial hearings last year. Barr, which filed an abbreviated new drug application for a generic version of Prozac, initiated the patent challenge in April 1996. The company expects a decision from the appeals court as early as the second calendar quarter of 2000. On Jan. 24, 1999, Eli Lilly alleged two competitors infringed on its Prozac patent rights. At the time, Barr and a unit of Novartis AG (Z.NOV) said the patents are faulty and they should be allowed to produce a cheaper, generic version of the drug. -Eamon Beltran; Dow Jones Newswires; 201-938-5400